RxDoctor Payments DataLook up a doctor →

Tawfik Chami, MD

Gastroenterology · Zephyrhills, FLNPI 1730198052

Payments from drug & device makers

$1,647,341in general payments, 2019–2025

Across 1,508 payments — averaging $1092.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$645K
  • Pfizer$342K
  • AbbVie$262K
  • Intercept Pharma Europe Ltd.$109K
  • Gilead$69K
  • Novo Nordisk AS$46K
  • plus $174K from 41 others

What the payments were for

  • Consulting fees$280%
  • Speaking & faculty fees$3,60017%
  • Travel & lodging$2,24511%
  • Food & beverage$15,10572%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647,341 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$126,302
Medicare patients
397
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase63$129,521
Humira(Cf)Adalimumab13$88,194
LinzessLinaclotide70$73,915
ClenpiqSod Picosulf/Mag Ox/Citric Ac200$33,770
ZenpepLipase/Protease/Amylase14$27,515
Sucralfate202$8,829
Mesalamine19$8,478
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates131$7,985
Colestipol Hcl91$7,683
Balsalazide Disodium17$4,727
Famotidine365$4,629
Pantoprazole Sodium424$4,519
Omeprazole250$3,654
Ursodiol25$3,572
Budesonide DrBudesonide18$1,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Humira(Cf), Linzess$262,246$291,630146 claims
Ferring Pharmaceuticals Inc.Clenpiq$289$33,770200 claims
Aimmune Therapeutics, Inc.Zenpep$179$27,51514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →